Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer.

about

Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer.

Item

http://www.wikidata.org/entity/Q42731854

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Outcome for esophageal cancer ...... reatment of esophageal cancer.

@en

Outcome for esophageal cancer ...... reatment of esophageal cancer.

@nl

type

Item

label

Outcome for esophageal cancer ...... reatment of esophageal cancer.

@en

Outcome for esophageal cancer ...... reatment of esophageal cancer.

@nl

prefLabel

Outcome for esophageal cancer ...... reatment of esophageal cancer.

@en

Outcome for esophageal cancer ...... reatment of esophageal cancer.

@nl

P1476

Outcome for esophageal cancer ...... treatment of esophageal cancer

@en

P2093

Ahmad Mardzuki

http://www.w3.org/2001/XMLSchema#string

Alexander McQuinn

http://www.w3.org/2001/XMLSchema#string

David I Watson

http://www.w3.org/2001/XMLSchema#string

Dennis Divalentino

http://www.w3.org/2001/XMLSchema#string

Sarah K Thompson

http://www.w3.org/2001/XMLSchema#string

P2860

Palliation of malignant dysphagia in esophageal cancer: a literature-based review.

Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.

The use of chemoradiotherapy in oesophageal cancer.

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer

Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus.

Radiochemotherapy of esophageal cancer.

Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens.

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

A phase I/II study to evaluate the toxicity and efficacy of accelerated fractionation radiotherapy for the palliation of dysphagia from carcinoma of the oesophagus.

Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences.

P304

75-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEG.S6273

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Urs Zingg

Christos S Karapetis

P577

2009-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21694830

http://www.w3.org/2001/XMLSchema#string

P932

3108630

http://www.w3.org/2001/XMLSchema#string